Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
References |
1: Babot-Marquillas C, Sánchez-Martín MJ, Amigo JM, Yousef I, H Valido I, Boada R, Valiente M. Tooth whitening effects on dental enamel, oxidation or reduction? Comparison of physicochemical alterations in bovine enamel using Synchrotron- based Micro-FTIR. Dent Mater. 2022 Apr;38(4):670-679. doi: 10.1016/j.dental.2022.02.006. Epub 2022 Mar 5. PMID: 35256209. 2: Sa Y, Jiang T, Li BY, Wang ZJ, Wang ZH, Wang YN. [Effects of three at-home bleaching agents on enamel structure and structure-related mechanical properties]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2012 May;47(5):281-6. Chinese. doi: 10.3760/cma.j.issn.1002-0098.2012.05.007. PMID: 22883823. 3: Zhao W. Measurement of Raman χ(3) and theoretical estimation of DOVE four wave mixing of hydrogen peroxide. J Phys Chem A. 2011 Jun 23;115(24):6525-30. doi: 10.1021/jp202977v. Epub 2011 May 18. PMID: 21591714. 4: Cao S, Sun LQ, Wang M. Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide. Ann Clin Microbiol Antimicrob. 2011 Jan 14;10:1. doi: 10.1186/1476-0711-10-1. PMID: 21232163; PMCID: PMC3031213. 5: Sun J, Hu Y, Cao S, Zhang G, Sun LQ, Wang M. Acute, multiple-dose dermal and genetic toxicity of Nu-3: a novel antimicrobial agent. J Biomed Biotechnol. 2010;2010:362524. doi: 10.1155/2010/362524. Epub 2010 Jul 20. PMID: 20706607; PMCID: PMC2914288. 6: Xue W, He H, Zhu J, Yuan P. FTIR investigation of CTAB-Al-montmorillonite complexes. Spectrochim Acta A Mol Biomol Spectrosc. 2007 Jul;67(3-4):1030-6. doi: 10.1016/j.saa.2006.09.024. Epub 2006 Sep 27. PMID: 17289428. 7: Feng M, Tachikawa H, Wang X, Pfister TD, Gengenbach AJ, Lu Y. Resonance Raman spectroscopy of cytochrome c peroxidase variants that mimic manganese peroxidase. J Biol Inorg Chem. 2003 Sep;8(7):699-706. doi: 10.1007/s00775-003-0460-9. Epub 2003 Jul 9. PMID: 14505074. 8: Pleshko NL, Boskey AL, Mendelsohn R. An FT-IR microscopic investigation of the effects of tissue preservation on bone. Calcif Tissue Int. 1992 Jul;51(1):72-7. doi: 10.1007/BF00296221. PMID: 1393781. 9: Oosterhof GO, Smits GA, de Ruyter AE, Schalken JA, Debruyne FM. Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. Ultrasound Med Biol. 1991;17(4):391-9. doi: 10.1016/0301-5629(91)90139-n. PMID: 1949350. 10: Combes M, Moroz VI, Crovisier J, Encrenaz T, Bibring JP, Grigoriev AV, Sanko NF, Coron N, Crifo JF, Gispert R, Bockelée-Morvan D, Nikolsky YuV, Krasnopolsky VA, Owen T, Emerich C, Lamarre JM, Rocard F. The 2.5-12 micrometers spectrum of comet Halley from the IKS-VEGA experiment. Icarus. 1988;76:404-36. doi: 10.1016/0019-1035(88)90013-9. PMID: 11538667.
|
---|
Molecular Formula |
C18H32N2O11P2
|
---|---|
Molecular Weight |
514.405
|
Exact Mass |
514.15
|
Elemental Analysis |
C, 42.03; H, 6.27; N, 5.45; O, 34.21; P, 12.04
|
CAS # |
403717-06-6
|
Appearance |
Solid powder
|
SMILES |
CCCCOP(=O)(O)OC[C@H]1O[C@H](C[C@@H]1OP(=O)(O)OCCCC)N2C=C(C)C(=O)NC2=O
|
InChi Key |
ZXQBUNYVGNOEBQ-ARFHVFGLSA-N
|
InChi Code |
InChI=1S/C18H32N2O11P2/c1-4-6-8-27-32(23,24)29-12-15-14(31-33(25,26)28-9-7-5-2)10-16(30-15)20-11-13(3)17(21)19-18(20)22/h11,14-16H,4-10,12H2,1-3H3,(H,23,24)(H,25,26)(H,19,21,22)/t14-,15+,16+/m0/s1
|
Chemical Name |
((2R,3S,5R)-3-((butoxy(hydroxy)phosphoryl)oxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl butyl hydrogen phosphate
|
Synonyms |
Bisphosphocin NU-3; NU-3; NU 3; NU3;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9440 mL | 9.7199 mL | 19.4397 mL | |
5 mM | 0.3888 mL | 1.9440 mL | 3.8879 mL | |
10 mM | 0.1944 mL | 0.9720 mL | 1.9440 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.